MedTrace Logo

Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.

NCT07420985 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-02-19

No results posted yet for this study

Summary

The objective of this study is to investigate the efficacy, safety, and tolerability of investigational product Ingavirin forte capsules (Valenta Pharm JSC) administered at different doses compared with medicinal product Ingavirin, 90 mg, capsules (Valenta Pharm JSC) in subjects with influenza or other acute respiratory viral infections (ARVIs).

Conditions

  • Influenza
  • Acute Respiratory Viral Infection

Interventions

DRUG

Ingavirin Forte, 90 mg + 5 mg, Capsules

90 mg + 5 mg, 1 capsule twice a day, for 5 days

DRUG

Ingavirin Forte, 90 mg + 10 mg, Capsules

90 mg + 10 mg, 1 capsule twice a day, for 5 days

DRUG

Ingavirin Forte, 90 mg + 20 mg, Capsules

90 mg + 20 mg,1 capsule twice a day, for 5 days

DRUG

Ingavirin, 90 mg, Capsules

90 mg, 1 capsule twice a day, for 5 days

DRUG

Placebo

1 capsule twice a day, for 5 days

Sponsors & Collaborators

  • Valenta Pharm JSC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-24
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07420985 on ClinicalTrials.gov